Reactivation of cutaneous psoriasis during abatacept therapy for spondyloarthropathy.
Florent
Amélie
A
Albert
Christine
C
Giacchero
Damien
D
Roux
Christian
C
Euller-Ziegler
Liana
L
D000069594:Abatacept; D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000009:adverse effects*; D005260:Female; D006801:Humans; D018796:Immunoconjugates / Q000009:adverse effects*; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology; D012008:Recurrence; D013167:Spondylitis, Ankylosing / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D016896:Treatment Outcome; D028761:Withholding Treatment
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D018796:Immunoconjugates; D007166:Immunosuppressive Agents; D000069594:Abatacept; D000068879:Adalimumab